Vyleesi

Vyleesi: Another Attempt to Profit from Women’s Health 

By NWHN Staff | Dec 23, 2019 | Comments Off on Vyleesi: Another Attempt to Profit from Women’s Health 

In June, the Food and Drug Administration (FDA) approved bremelanotide (brand name Vyleesi) to treat a lack of sexual desire in premenopausal women.1 The NWHN advocated against the drug’s approval, and spoke in opposition when the approval announcement was made. Here’s why.  

Vyleesi Fact Sheet

By NWHN Staff | Jul 12, 2019 | Comments Off on Vyleesi Fact Sheet

Bremelanotide (brand name: Vyleesi) is a drug approved by the FDA to treat a lack of sexual desire (hypoactive sexual desire disorder) in premenopausal women.

The NWHN’s Statement on the FDA’s Approval of Vyleesi

By Cindy Pearson | Jun 21, 2019 | Comments Off on The NWHN’s Statement on the FDA’s Approval of Vyleesi

FOR IMMEDIATE RELEASE Contact: Evita Almassi, ealmassi@nwhn.org or 425-749-1886

Top 10 Things to Know About Today’s Sex Drive Drugs

By NWHN Staff | Oct 15, 2015 | Comments Off on Top 10 Things to Know About Today’s Sex Drive Drugs

Learn about Addyi (flibanserin) and Vyleesi (bremelanotide), FDA-approved drugs designed to treat hypoactive sexual desire disorder (HSDD) in premenopausal women.